Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Reich

Showing results (271-280 of 316) with videos related to

Pageof 32
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|November 8, 2025
The SWITCH algorithm: An expert consensus on treat-to-target criteria for chronic prurigoLea S Stahl, Claudia Zeidler, Joyce Loewenthal, et al.
The British Journal of Dermatology|July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 28, 2026
The nuclear receptor TR4 orchestrates cytoskeletal organization in a Gα12/ROCK-dependent manner to promote myofibroblast differentiation and tissue fibrosis in systemic sclerosisYun Zhang, Lichong Shen, Junhui Zheng, et al.
Biomed Research International|August 28, 2018
Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional StudyDominik Samotij, Justyna Szczęch, Carolyn J Kushner, et al.
Immunotherapy|September 1, 2025
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical studyStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Journal of Clinical Medicine|February 25, 2023
Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from PolandMichał Adamczyk, Joanna Bartosińska, Dorota Raczkiewicz, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Journal of the American Academy of Dermatology|August 19, 2018
Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trialSabine Steinke, Claudia Zeidler, Claudia Riepe, et al.
Lupus|May 18, 2021
Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional studyDominik Samotij, Justyna Szczęch, Emiliano Antiga, et al.
Dermatology and Therapy|November 21, 2024
Characteristics of Patients with Generalized Pustular Psoriasis: A Report of the Polish Generalized Pustular Psoriasis GroupMarta Kołt-Kamińska, Luiza Marek-Józefowicz, Piotr Krajewski, et al.
Pageof 32

Showing results (271-280 of 316) with videos related to

Sort By:
Pageof 32
Journal of the European Academy of Dermatology and Venereology : JEADV|November 8, 2025
The SWITCH algorithm: An expert consensus on treat-to-target criteria for chronic prurigoLea S Stahl, Claudia Zeidler, Joyce Loewenthal, et al.
The British Journal of Dermatology|July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 28, 2026
The nuclear receptor TR4 orchestrates cytoskeletal organization in a Gα12/ROCK-dependent manner to promote myofibroblast differentiation and tissue fibrosis in systemic sclerosisYun Zhang, Lichong Shen, Junhui Zheng, et al.
Biomed Research International|August 28, 2018
Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional StudyDominik Samotij, Justyna Szczęch, Carolyn J Kushner, et al.
Immunotherapy|September 1, 2025
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical studyStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Journal of Clinical Medicine|February 25, 2023
Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from PolandMichał Adamczyk, Joanna Bartosińska, Dorota Raczkiewicz, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Andrew Blauvelt, Kim A Papp, et al.
Journal of the American Academy of Dermatology|August 19, 2018
Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trialSabine Steinke, Claudia Zeidler, Claudia Riepe, et al.
Lupus|May 18, 2021
Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional studyDominik Samotij, Justyna Szczęch, Emiliano Antiga, et al.
Dermatology and Therapy|November 21, 2024
Characteristics of Patients with Generalized Pustular Psoriasis: A Report of the Polish Generalized Pustular Psoriasis GroupMarta Kołt-Kamińska, Luiza Marek-Józefowicz, Piotr Krajewski, et al.
Pageof 32